Further Experience with Rezoxane (ICRF 159; – NSC – 129943) in Treating Kaposi’s Sarcoma

Abstract

47 patients with histologically proven Kaposi’s sarcoma were treated with multiple courses of Rezoxane (each course: 1 g/m²/day for 3 days) orally. The overall response was 57% with 20% achieving complete response. The median remission duration of the complete responders is 12 months (range 2–26) with 6 still having sustained complete remissions. Most of the responders were patients with nodular mixed type of Kaposi’s sarcoma. The toxicity was minimal and was mainly leukopenia, alopecia and gastrointestinal disturbance. Rezoxane is a useful safe drug and easy to administer to patients with Kaposi’s sarcoma.

Argon Laser Photocoagulative Therapy of Kaposi's Sarcoma: A Clinical and Histologic Evaluation

“…Systemic therapy may be necessary, depending upon the extent of the disease since the 3‐year survival rate is only 64% in the common African form. For the aggressive generalized form of KS seen in association with AIDS, systemic chemotherapy generally remains the treatment of choice 26–37 …”

“…A variety of treatment modalities for KS have been used in the past with varying degrees of success. Some of these include: radiotherapy; 20–24 hyperthermia; 25 chemotherapy 26 using such agents as nitrogen mustard, 27 vinblastine, 28,29 vincristine, 30,31 DTIC, 32 bleomycin, 33 rezoxane, 34 etoposide, 35 cyclophosphamide, 36 BCNU, doxorubicin, 37 and dapsone; 38 immunotherapy; 39,40 interferon; 41–43 surgical excision and amputation; 44,45 ruby laser; 46 and, photodynamic therapy using a dye laser 47,48 …”

The evolution of a cardioprotective antimetastatic and antitumor drug: An international adventure

“…Subsequently, has undergone extensive clinical investigations. Treatment with this compound has shown partial remission in patients having acute leukemia and lymphosarcoma (7), non-Hodgkins lymphoma (8), Kaposi's sarcoma (9), and psoriasis (10). This drug was not particularly useful in the treatment of advanced bronchogenic cancer (11), malignant melanoma (12), carcinoma of the breast (13,14), squamous cell carcinoma of the head and neck (15), advanced gastric cancer (16), and pediatric solid tumors (17).…”

Interference with in vivo growth and metastasis of prostate adenocarcinoma (PA‐III) by ICRF‐159

“…However, this drug did not interfere with metastasis of a rat epithelioma [lo] nor of B16 melanoma cells [ll]. It manifested equivocal benefits on cancers of the colon and breast, Kaposi's sarcoma, melanoma, and of lymphomas in man [12,13], and as adjuvants with other drugs. tasis of PA-I11 cells have been suppressed or retarded.…”